Everand Logo

Welcome to Everand!

  • STAT

    Before a biotech stock debacle, one Republican congressman made a prescient trade

    Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech's stock tanked. The stock was a favorite of several GOP representatives.
    by Damian Garde Jul 03, 2017 2 minutes
    Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech company's stock tanked.

    A biotech stock meltdown last week led to huge paper losses for several congressional Republicans who had bought into the tiny company. But one politician-turned-investor was spared. Turns out, he had sold his shares just two weeks before news of a negative clinical trial decimated the company’s value.

    Rep. John Culberson of Houston was among a half dozen House Republicans to invest in Innate Immunotherapeutics,

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks